Mibavademab
- Generic Name
- Mibavademab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2305770-44-7
- Unique Ingredient Identifier
- PHL2UDY3AB
- Background
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06548100
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- 🇺🇸
Hassman Research Institute Marlton Site, Marlton, New Jersey, United States
🇺🇸CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Velocity Clinical Research, Gardena, Gardena, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath